BiotechTube
OncoOne

OncoOne

Vienna, Austria· Est.
oncoone.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $16M

Overview

OncoOne is a private, preclinical-stage biotech based in Vienna, Austria, pioneering next-generation targeted cancer therapies. The company's core assets are two distinct but complementary technology platforms: the Anti-oxMIF platform targeting a novel tumor-associated form of the macrophage migration inhibitory factor (MIF), and the PreTarg-it® platform, a modular system for pre-targeted radioimmunotherapy designed to enhance precision and safety. Currently seeking Series A+/B financing and strategic partnerships, OncoOne aims to advance its pipeline of highly differentiated candidates into clinical development for oncology and chronic inflammatory diseases.

OncologyChronic Inflammation

Technology Platform

Two proprietary platforms: 1) Anti-oxMIF Platform for generating antibodies selectively targeting the oxidized form of MIF (oxMIF), a novel tumor-associated antigen. 2) PreTarg-it® Platform, a modular bispecific antibody system for pre-targeted radioimmunotherapy (PRIT) designed to enhance tumor targeting and reduce systemic radiation exposure.

Funding History

2
Total raised:$16M
Series A$12M
Seed$4M

Opportunities

The rapidly expanding global radiopharmaceutical therapeutics market and the high unmet need for novel, tumor-selective targets in oncology present a significant opportunity.
OncoOne's modular PreTarg-it® platform is well-positioned for strategic partnerships, allowing the company to generate revenue and validate its technology with multiple targets alongside its proprietary oxMIF programs.

Risk Factors

Key risks include the preclinical validation of oxMIF as a target and the clinical performance of the novel PreTarg-it® platform, the company's dependence on securing a Series A+/B financing round to advance programs, and intense competition in the targeted therapy and radiopharmaceutical spaces from larger, better-resourced companies.

Competitive Landscape

OncoOne competes in the targeted antibody and radiopharmaceutical sectors. For Anti-oxMIF, it faces competition from all companies developing targeted oncology biologics. For PreTarg-it®, direct competitors include other companies developing next-generation radioimmunotherapies (e.g., Actinium Pharmaceuticals, RayzeBio, Mariana Oncology) and established radioligand therapy players like Novartis. Differentiation hinges on the unique oxMIF target and the claimed safety/efficacy benefits of the pre-targeting approach.

More companies in Small Molecule Drugs →More companies in Austria →